Arvinas Holding Company (ARVN) has provided an announcement.
Arvinas, Inc. has announced significant leadership changes with Ian Taylor, Ph.D. stepping in as the new president of R&D and Angela Cacace, Ph.D. taking over as chief scientific officer. Dr. Cacace, who has been with the company since 2018, will advance the research pipeline, while Dr. Taylor will provide strategic guidance for the company’s various projects in oncology and neuroscience, along with chairing the scientific advisory board. These appointments, approved by the board, mark a new chapter for Arvinas’s innovation and development efforts.
For a thorough assessment of ARVN stock, go to TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
